Our clinical pipeline is comprised of drug candidates and potential drug candidates that have arisen from our knowledge and expertise regarding the cytoskeleton. These clinical programs are focused on muscle contractility and oncolgy.

We are currently developing four small molecule compounds arising from our muscle contractility programs. Omecamtiv mecarbil (CK-1827452), a novel cardiac muscle myosin activator, is currently in Phase IIa clinical trials for the potential treatment of heart failure. CK-2017357 is our lead drug candidate from our skeletal muscle contractility program and is in Phase IIa clinical trials. We are evaluating the potential indications for which this compound may be useful. These may include skeletal muscle weakness associated with neuromuscular diseases and other medical conditions characterized by skeletal muscle weakness or wasting. We have selected a second potential drug candidate from this program that may serve as a backup compound to CK-2017357. We are also developing an inhaled inhibitor of smooth muscle myosin as a bronchodilator, which is currently in IND-enabling studies. We are continuing to conduct discovery, characterization and lead optimization activities for other compounds with the potential to modulate muscle contractility and other muscle functions.

We also currently have three drug candidates in clinical trials for the potential treatment of cancer: ispinesib, SB-743921 and GSK-923295. These three small molecule drug candidates target mitotic kinesins for application in the treatment of cancer and other diseases. Mitotic kinesins are a family of cytoskeletal motor proteins involved in the process of cell division, or mitosis. We have focused primarily on two mitotic kinesins: kinesin spindle protein (“KSP”) and centromere-associated protein E (“CENP-E”).